Description: Ostermed is a Pharmaceutical Consultancy based in Canterbury, Kent, UK.
consultancy (5003) pharmaceutical (1236) vascepa (14) ostermed (9) esmya (9)
We would like to congratulate two of our client companies on achieving regulatory approval of their first products in Europe and USA.
On the 23rd February 2012, the European Commission granted PregLem Ltd, (now a division of Gedeon Richter) approval of Esmya™ (ulipristal acetate) for the pre-operative treatment of uterine fibroids.
Uterine fibroids are common benign tumours affecting between 20 and 25% of women of reproductive age. Approximately 300,000 surgical procedures are performed annually in the EU for uterine fibroids. The main symptoms are excessive uterine bleeding, anaemia, pain, frequent urination, and infertility. British Fibroid Trust. Until now, Gonadotrophin Releasing Hormone (GnRH) agonists were the only approved pre-operative treatment for uterine fibroids and their use has been relatively limited due to side effects